華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE SIX MONTHS ENDED 30 JUNE 2022

On 14 July 2022, Dong-E-E-Jiao released its results estimate for the six months ended 30 June 2022.

Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) ("**Dong-E-E-Jiao**") is a company incorporated in the People's Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 8.86% of its equity interests by China Resources Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") and approximately 23.14% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司). The Group effectively controls approximately 21.96% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 14 July 2022, Dong-E-E-Jiao released its results estimate for the six months ended 30 June 2022. In which, it announced that the net profit attributable to the shareholders of Dong– E-E-Jiao for the six months ended 30 June 2022 would range from approximately RMB270 million to RMB340 million, representing an increase between 80% and 127% as compared to the net profit of approximately RMB149.64 million for the same period last year, net profit excluding non-recurring gain or loss is estimated to range from approximately RMB250 million to RMB330 million, representing an increase between 132% and 206% as compared to the net profit excluding non-recurring gain or loss of approximately RMB107.99 million for the same period last year, and basic earnings per share is estimated to range from approximately RMB0.42 per share to approximately RMB0.53 per share (as compared to the same period last year of profit per share of approximately RMB0.23 per share) (the "**Dong-E-E-Jiao Results Estimate**").

The main reasons for the change in results are set forth as follows:

1. Dong-E-E-Jiao advanced "14th Five-Year-Plan" strategic planning with solid efforts, consistently optimizing its product mix and upgrading its product portfolio in close tandem with the strategic mainstay focused on consumer requirement, while implementing a customer-centric digital operational model in an intensive manner to deepen extensive expansion and innovative exploration of product varieties, thereby achieving growth in customers and business results.

2. Dong-E-E-Jiao will continue to fortify its leading position in the TCM nutrition sector in China as "Dong-E-E-Jiao the national treasure in nutrition" in accordance with the principle of qualitative development and make probing advances in "value reshaping, business reshaping, organisational reshaping and ethos reshaping", and to solidify its three major core products and make breakthroughs in the functional health supplement category based on a development strategy underpinned by "consolidation of principal businesses, extended breakthroughs and innovative exploration". Solutions will be provided according to market and customer requirements, while digital organisational competence and innovative vigor will be enhanced to consistently improve its profitability and operational efficiency and attain positive and healthy development for the company.

The Dong-E-E-Jiao Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For the details of financial data, those to be disclosed in the interim report for the six months ended 30 June 2022 to be issued by Dong-E-E-Jiao shall prevail.

The financial information in this announcement is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational of financial status of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 15 July 2022

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mr. Tan Ying, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.